440
Views
17
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Intermediate prognosis of 6q deletion in chronic lymphocytic leukemia

, , , , , , , & show all
Pages 230-237 | Received 05 Oct 2010, Accepted 19 Nov 2010, Published online: 01 Feb 2011
 

Abstract

Cytogenetic features have an important role in the definition of distinct disease subsets in CLL. The deletion of 6q is known to occur at a relatively low frequency in CLL, and the detailed analysis of hematologic and clinical features of patients with CLL with 6q deletion is limited. To verify the incidence and prognostic significance of 6q deletion in Chinese patients with CLL, fluorescence in situ hybridization (FISH) was used in 240 patients with CLL. del(6q23) was found in 18 patients (7.5%), and only five patients had deletion in 6q23 as the sole abnormality. Strong correlations between del(6q23) and clinical parameters were not found. A difference in terms of survival in patients with del(6q23) as compared with patients without this anomaly was not able to be demonstrated. However, a significant difference was found when comparing the del(6q23) group with the del(17p13) or del(11q22.3) group (p = 0.023), or isolated del(13q14) group (p = 0.019). Our findings place the del(6q23) cytogenetic subset of CLL in an intermediate prognosis position between patients with del(11q22.3) or del(17p13), and patients with isolated del(13q14). FISH probes to detect deletions of 6q might be useful in clinical practice in the work-up of patients with CLL.

Declaration of interest: This study was supported by the National Natural Science Foundation of China (30871104, 30971295, 30971296, 81000216), Jiangsu Province's Outstanding Medical Academic Leader Program (LJ200623), Jiangsu Province's Medical Elite Program (RC2007042), the Natural Science Foundation of Jiangsu Province (BK2010584), ‘Qing Lan’ project of Jiangsu Province, and ‘Liu Da Ren Cai Gao Feng’ of Jiangsu Province.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.